Good day and welcome to the Intellia Therapeutics 2025 Annual Meeting of Stockholders. I would now like to turn the conference over to Dr. Frank Verwiel, Chairperson of the company's Board of Directors, to proceed with the 2025 Annual Meeting of Stockholders. Dr. Verwiel, please go ahead. Thank you. Good morning. I'm Dr. Frank Verwiel, Chairperson of the Board of Intellia Therapeutics. I will act as the chairperson of this meeting. I am pleased to welcome you to the Intellia 2025 Annual Meeting of Stockholders. Before I call the meeting to order, I would like to introduce you to the members of our board and our executive team who are with us today. The other members of the board that are with us today are Muna Bhanji, William Chase, Dr. Fred Cohen, Brian Goff, Dr. Jesse Goodman, Dr. Georgia Keresky, and Dr. John Leonard, our President and Chief Executive Officer. The other officers and members of the management of the company with us today are Tim Basta, General Counsel and Corporate Secretary, Dr. Eliana Clark, Chief Technology Officer, Edward Dulac, Chief Financial Officer, Mike Duby, Chief Accounting Officer, and then Mr. Lev, Associate General Counsel. Mr. Basta will act as the Secretary and Mr. Lev will act as the inspector of elections for this meeting. Mr. Lev has taken and subscribed to the customary oath of office to execute his duties with strict impartiality, which will be filed with the records of the meeting. I also would like to introduce Jim Holtz of Deloitte & Touche LLP, the company's independent registered public accounting firm, who is available to respond to appropriate questions. The meeting will now officially come to order. We propose to proceed with the formal business of the meeting as set forth in the company's 2025 Notice of Annual Meeting and Proxy Statement. We request that if you have questions, please submit them following the instructions provided on the virtual meeting screen and described in the rules of conduct. Will the secretary please report at this time on the mailing of the notice for this meeting and the stockholders list? I have at this meeting a complete list of the stockholders of record of the company at the close of business on April 14, 2025, the record date for this meeting. I also have an affidavit certifying that commencing on April 30, 2025, the notice of Internet Availability of Proxy Materials was deposited in the United States mail to all stockholders of record as of April 14, 2025. Will the Secretary please report at this time with respect to the existence of a quorum. I've been informed by the Inspector of Elections that proxies have been received for $82,824,215 of the $103,582,731 shares of common stock outstanding on the record date, which represents approximately 80% of the total number of shares entitled to vote at this meeting. This constitutes a quorum for the meeting today and we may now carry out the official business of the meeting. Are there any additional proxies to be submitted to the Inspector of Elections at this time? Verwiel? There have been no additional proxies submitted. To me at this time. Thank you. We will now proceed with the formal business of this meeting. The following proposals are to be considered by our stockholders at this meeting. Proposal one is the election of three Class 3 Directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders or until their successor has been duly appointed, duly elected and qualified, or until their earlier death, resignation, or removal. Proposal two is the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Proposal three is the approval on a non-binding advisory basis of the compensation of our Named Executive Officers, also known as NEO. Proposal four is a non-binding advisory vote on the frequency of the non-binding advisory votes on the compensation of our NEO. Proposal 5 is the approval of the Intellia Therapeutics 2025 Equity Incentive Plan. Proposal 6 is a transaction of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. Those were the final proposals for today's meetings. The Secretary will now describe the voting procedures. The time is now 9:05 A.M. Eastern Time on Wednesday, June 11, 2025, and the polls are now open for voting on the proposals described by the Chairperson. All Intellia stockholders entitled to vote at this meeting have the ability to do so online. You do not need to vote again if you have already voted your proxy online, by telephone, or by mail and do not wish to change your vote. However, if you have either not voted already or if you want to change your previous vote, you may do so now in accordance with the instructions on your virtual meeting screen and as described in the Rules of Conduct. We'll now wait for a brief moment. The time is now 6:06 A.M. Eastern Time and the polls are now closed for voting. May we have the results of the voting? The report of the Inspector of Elections covering the proposals presented at this meeting is as follows. Proposal 1 for the election of William Chase, Dr. Georgia Keresky and Dr. John Leonard as Class 3 Directors of the company has been approved. Proposal 2 for the ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 has been approved. Proposal 3 for the approval on a non-binding advisory basis of the compensation of our NEOs, has been approved. Proposal 4, which is the non-binding advisory vote on the frequency of future non-binding advisory votes on the compensation of our NEOs, the majority of votes are for one year. Proposal 5 for the approval of the Intellia Therapeutics 2025 Equity Incentive Plan has been approved. Thank you. There being no other business to properly come before this meeting, let us pause for a moment to compile any questions that have been submitted via the online portal regarding only the matters that have been discussed in this formal portion of the Annual Meeting. Will the secretary please advise if we have any questions? There are no questions. We have no questions appropriately related to the purpose of this meeting. There being no other business to probably come before this meeting. This meeting is now adjourned. Thank you for attending Intellia Therapeutics 2025 Annual Meeting of Stockholders. This now concludes the meeting. Thank you for joining and have a pleasant day. The host has ended this call. Goodbye.